Gene therapy in PIDs, hemoglobin, ocular, neurodegenerative, and hemophilia B disorders

A new approach is adopted to treat primary immunodeficiency disorders, such as the severe combined immunodeficiency (SCID; e.g., adenosine deaminase SCID [ADA-SCID] and IL-2 receptor X-linked severe combined immunodeficiency [SCID-X1]). The success, along with the feasibility of gene therapy, is und...

Descripción completa

Detalles Bibliográficos
Autores principales: Odiba, Arome Solomon, Okoro, Nkwachukwu Oziamara, Durojaye, Olanrewaju Ayodeji, Wu, Yanjun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: De Gruyter 2021
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8093481/
https://www.ncbi.nlm.nih.gov/pubmed/33987480
http://dx.doi.org/10.1515/biol-2021-0033

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8093481/
https://www.ncbi.nlm.nih.gov/pubmed/33987480
http://dx.doi.org/10.1515/biol-2021-0033

Ejemplares similares